Background: Hepatic-artery and para-aortic lymph node metastases (LNM) may be detected
INTRODUCTION
Pancreatic and periampullary cancer remain a deadly disease. Five-year survival rates are as low as 5%. 1, 2 In pancreatic cancer, forty percent of patients present with locally advanced disease, with an overall survival following palliative chemotherapy of 10 months. 3, 4 In those patients with metastatic disease survival (7 months) is even shorter. 5 Surgery is feasible in 20% of patients, and following adjuvant chemotherapy may achieve a 5-year survival rate of 20%. 6 Following resection of periampullary cancer, 5-year survival may reach 20-50%. 7 As such, currently the best survival rates are achieved with resection, and adjuvant chemotherapy. As operative techniques and perioperative outcomes continue to improve, optimizing the eligibility criteria for resection is of great interest. 6, 8 Furthermore, due to limited survival times, identifying those patients who do not benefit from a resection is equally important.
Lymph node metastases (LNM) are regarded as a strong negative prognostic factor in patients with pancreatic and periampullary cancer, and most studies have focused on the hepatic-artery (station 8a) and para-aortic (station 16b1) lymph nodes. In most centers, patients with preoperatively detected extra-regional LNM do not undergo resection. 9, 10 A standard lymphadenectomy, which includes the hepatic-artery but not para-aortic lymph nodes, was recently defined by the International Study Group of Pancreatic Surgery (ISGPS). 11 As preoperative imaging is often not reliable to exclude LNM, intraoperative detection of extra-regional LNM regularly confronts surgeons with the decision to abort the exploration or continue with resection. 12 The primary aim of this study was to perform a systematic review and meta-analysis to determine survival after pancreatoduodenectomy or aborted exploration in patients with intra-operatively detected hepatic-artery and para-aortic LNM in pancreatic and periampullary cancer. The secondary aim of this study was to compare survival between patients with hepatic-artery or para-aortic LNM versus other N1 disease.
METHODS

Study selection
A systematic review was performed according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. 13 search, LB and NCM for the second search) screened title and abstract for eligibility. Discrepancies were solved through discussion and consensus, and in case of any doubt resolved with the senior author. Next, the eligibility of full text articles was assessed similarly. References of finally included articles were checked manually for studies that had not been identified in the primary search.
Study eligibility and outcomes
Studies investigating the prognostic value of LNM on overall survival in patients with pancreatic cancer were considered eligible. From studies of patients undergoing resection, only patients undergoing pancreatoduodenectomy were included. Reviews, case reports and editorials were excluded. Study and baseline characteristics, LNM location and survival outcomes were obtained.
LNM-specific data were analyzed if in total, there were at least 75 node positive patients per lymph node station involved. This was an arbitrary cut-off, chosen to obtain sufficient data for a robust analysis. Attention was paid to the characteristics of the control group; whether they consisted of node negative (N0) patients or patients with node positive (N1) disease, but negative to the specific lymph node station being analyzed.
Assessment of methodological quality
Methodological quality was assessed using the Oxford Centre for Evidence-Based Medicine Levels of Evidence. 14 Risk of bias in each of the included studies was assessed using the Newcastle-Ottawa Quality Assessment Scale for cohort studies. 15 The criteria for 'comparability' in the NewcastleOttawa Quality Assessment Scale to assess varieties within the arranged cohort was used for a complete analysis.
Statistical analysis
To perform a meta-analysis, using the random effects model, pooled mean survival was estimated using a validated and widely used formula. 16 This formula estimates the mean, variance and standard deviation of a sample using the reported sample size, median and range. If not reported, median survival and ranges were deducted from Kaplan-Meier curves. In these cases, if patients were alive at last follow-up, the maximum range was set at the time of censoring. Heterogeneity between studies was assessed using the I-squared statistic considering the following margins: low (0-40%), moderate (30-60%), substantial (60-90%) and considerable (75-100%) heterogeneity.
Meta-analysis was performed using Review Manager (The Nordic Cochrane Centre, The Cochrane Collaboration) version 5.3.17 Differences with P < 0.05 were considered statistically significant.
Sensitivity analysis was performed for patients with pancreatic ductal adenocarcinoma (PDAC) only.
RESULTS
Study selection
A total of 3088 articles were screened (first search 1255 articles, second search 2097 articles). The PRISMA flowchart for study selection regarding the first search (i.e. patients receiving resection)
is shown in Fig. 1 . The second search, despite extensive screening, revealed not a single study fulfilling the eligibility criteria. Finally in 13 full text articles were included a total of 2045 patients receiving pancreatoduodenectomy. Table 1 summarizes the characteristics of included studies. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] One study was excluded due to overlap in its patient population with another study assessing additionally extra-regional LNM. 29, 30 No studies were excluded due to inadequate methodological quality (Supplementary Table) . 
Hepatic-artery LNM (station 8a)
Survival data related to hepatic-artery LNM in patients receiving pancreatoduodenectomy are given in Table 2 . In total there were 539 patients; 110 (20%) patients with and 429 (80%) patients without hepatic-artery LNM. Median survival of patients with hepatic-artery LNM ranged between 7 and 17 months and 3-year survival was 0% in one study among 17 patients. In patients with N1-disease but without hepatic-artery LNM, median survival ranged from 16 to 21 months and 3-year survival was 23% among 60 patients in one study. 25 Estimated pooled mean survival was [15] [16] [17] [18] months in 84 patients with hepatic-artery LNM compared to 19 [16] [17] [18] [19] [20] [21] [22] months in 270 patients with N1-disease without hepatic-artery LNM.
Estimated pooled mean difference could be generated from 3 studies and was 3 [95%CI 0-5, p = 0.020] months. There was low statistical heterogeneity among these 3 pooled studies (I2 = 0%, p = 0.5). The assessed metastatic lymph node station was compared to N1/8a-and N0 patients together, instead of N1/8a-only. c P-value for difference in median survival.
Para-aortic LNM (station 16b1)
Survival data related to para-aortic LNM in patients receiving pancreatoduodenectomy are presented in Table 3 . In total there were 794 patients; 192 (24%) patients with and 602 (76%) patients without para-aortic LNM. Median survival of patients with para-aortic LNM ranged between 5 and 32 months and 3-year survival ranged between 0 and 3%, although the latter was deducted from 53 patients in two studies only. In patients with N1-disease but without para-aortic LNM median survival ranged between 13 and 34 months and 3-year survival was only reported in one study: 12% in 84 patients. 25 Estimated pooled mean survival was 13 [95%CI [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] months in 169 patients with para-aortic LNM compared to 17 months in 506 patients with N1-disease without para-aortic LNM.
Estimated pooled mean difference could be generated from 5 studies and was 5 [95%CI 2-7, P < 0.001] months. There was moderate statistical heterogeneity among these 5 pooled studies (I2 = 53%, p = 0.080).
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Sensitivity analysis
Sensitivity analysis was performed after excluding all non-PDAC cancers ( 
DISCUSSION
In the first systematic review on this subject, reduced survival was found following intraoperative detection of hepatic-artery or para-aortic LNM in patients undergoing pancreatoduodenectomy for cancer. Survival was reduced further in patients with para-aortic LNM, compared to patientswith hepatic-artery LNM. Data on survival in patients in whom the surgical exploration was aborted after intraoperative detection of LNM are lacking.
No studies were specifically designed to investigate if positive hepatic-artery, or para-aortic LNM should automatically preclude a resection in all patients. None of the included studies reported survival after aborted explorations due to detection of intraoperative LNM. Patients with metastasized pancreatic cancer have an overall survival of about 7 months when treated with gemcitabine and up to 11 months when treated with FOLFIRINOX, which is reserved for fitter patients. 5 Survival of patients with locally advanced pancreatic cancer is around 10 months.
3,4,32
The pooled data demonstrate that patients with (pancreatic) cancer and hepatic-artery LNM had an estimated pooled mean survival of 15 months. Estimated pooled mean survival following pancreatoduodenectomy with para-aortic LNM was 13 months. The interpretation of the aggregated data is challenging due to several factors. Most of the included studies performed lymph node sampling in a subset of patients only, although these indications were mostly not given. It could be based on a surgeon's preference, i.e. an intraoperative finding of macroscopically suspicious lymph nodes or patients with other risk factors for poor survival such as extensive disease. As such, lymph node sampling may have been selectively performed in patients with a poorer prognosis, leading to worse survival rates. Conversely, resection in case of LNM may have been performed in younger patients with fewer comorbidities, as it is felt these patients might still benefit from a resection. The influence of comorbid conditions on outcomes following surgery is well known. 33, 34 Furthermore, few data were available on (neo)adjuvant treatment, for instance with FOLFIRINOX, in the included studies. All studies described only the total number of patients receiving adjuvant or neoadjuvant treatment. They did not describe the number of patients with, or without LNM specifically receiving these treatments. Sensitivity analysis was performed for PDAC separately, as outcomes may differ from periampullary (distal CBD, papilla, duodenum) cancers, and clear differences exist in survival between the various periampullary cancers and PDAC. 35, 36 Therefore, some of the largest studies in this review describing only 'cancer of the pancreatic head' which may involve distal cholangiocarcinoma were excluded from sensitivity analysis. Survival in patients with PDAC and LNM was shorter compared to patients with other periampullary cancers and LNM: survival in patients with PDAC and hepatic-artery or para-aortic LNM was 13 and 11 months, respectively, compared to 15 and 13 months for all patients.
Estimated pooled mean difference in survival was not significant for PDAC patients with, or without hepatic-artery LNM undergoing resection. However, interpretation of the data remains difficult due to the issues raised above, and low patient numbers.
According to the TNM classification, para-aortic lymph nodes are extra-regional nodes for both pancreatic and periampullary cancer. According to the TNM, the hepatic-artery lymph node is either regional (pancreatic and bile duct cancer) or extra regional (ampullary cancer). 37 Recently, the ISGPS introduced a consensus definition of a standard lymphadenectomy in patients with pancreatic cancer which included the hepatic-artery lymph node, but not the para-aortic lymph nodes. 11 The ISGPS consensus was partly based on 4 randomized controlled trials (RCT's) investigating the value of an extended lymphadenectomy, which included various lymph node stations. [38] [39] [40] [41] Prior studies have demonstrated that both preoperative CT-imaging and visual inspection cannot reliably determine LNM. 12, 26 The accurate determination of (loco) regional LNM by endoscopic ultrasonography (EUS) even seems similar. [42] [43] [44] Extra-regional lymph nodes may not be visible on EUS. This suggests that in case of clinical consequences such as aborting a surgical exploration, standard intraoperative sampling of hepatic-artery and para-aortic lymph nodes should be performed. Previous studies have demonstrated that the para-aortic lymph node station is important in pancreatic lymphatic drainage. 45, 46 Indeed, occurrence of para-aortic LNM has been associated with LNM in more proximal nodes such as stations 13, 14 and other peripancreatic lymph nodes. 26, 29, 47 The method to estimate mean survival times using reportedmedians, ranges and sample sizes has been widely used and validated. 16 Although survival times may be skewed due to some patients surviving longer, the estimation is distribution-free. Furthermore, long-term survival following 239 LYMPH NODE METASTASES DURING SURGICAL EXPLOR ATION resection of pancreatic cancer is extremely rare, which restricts the skewness of survival data. 48 Attempts have been made to improve the estimations, but they remain to be validated. 49 Therefore the methods were used as described. Survival ranges needed to estimate mean survival times were deducted from Kaplan-Meier curves in 6 out of 7 studies of patients with para-aortic LNM. In these cases <10% of patients were alive at the end of follow-up. This has been taken into account when interpreting the pooled data. There was moderate statistical heterogeneity in the pooled studies regarding para-aortic LNM. However, the I-squared static has lower power when studies have small sample sizes. While the methodological quality of the included studies is adequate, studies were mostly small and retrospective. Large, prospective studies are needed to establish clinical risk models to determine if, and if so which patients might benefit of a resection. These studies should report outcomes of PDAC and peri-ampullary cancer separately. With the introduction of the ISGPS consensus on a standard lymphadenectomy, larger and prospective studies can now be performed and compared.
CONCLUSION
Hepatic-artery and especially para-aortic LNM detected during exploration for pancreatic or periampullary cancer is associated with reduced survival. Resection in patients with hepatic-artery LNM seems reasonable as survival times are better compared to patients with irresectable disease and this node is part of the ISGPS standard lymphadenectomy. In patients with para-aortic LNM proceeding with resection is less obvious, but due to a lack of adequate control groups and data on (neo)adjuvant therapy it remains unclear whether intra-operative detection of para-aortic LNM should automatically preclude resection in all patients.
